AbSci (ABSI)
NASDAQ:ABSI
Want to see ABSI full AI Analyst Report?
Top Page
AbSci
(NASDAQ:ABSI)
Select Model
Select Model
Rating:54Neutral
Price Target:
$5.00
▲(39.66% Upside)
Action:ReiteratedDate:04/28/26
The score is held down primarily by weak financial performance (large losses and significant ongoing cash burn despite low leverage). This is partially offset by a constructive earnings-call setup with defined ABS-201 milestones and runway into 2028, plus strong but overbought technical momentum. Valuation provides limited support given negative earnings and no dividend.
Positive Factors
Proprietary AI platform validation (de novo antibody design)
Demonstrated de novo, full-length antibody design with integrated lab validation establishes a durable technical moat. This capability can materially shorten discovery cycles, improve hit quality, and attract partnership deals, supporting recurring service revenues and platform licensing over multiple programs.
Negative Factors
High and persistent cash burn
Sustained large operating and free cash outflows materially drain liquidity and force reliance on external financing or partner deals. Even with low debt, high burn increases dilution or covenant risk, constrains discretionary investment, and elevates execution risk if clinical timelines slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary AI platform validation (de novo antibody design)
Demonstrated de novo, full-length antibody design with integrated lab validation establishes a durable technical moat. This capability can materially shorten discovery cycles, improve hit quality, and attract partnership deals, supporting recurring service revenues and platform licensing over multiple programs.
Read all positive factors
AbSci (ABSI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$873.61M
Dividend YieldN/A
Average Volume (3M)4.08M
Price to Earnings (P/E)―
Beta (1Y)2.25
Revenue Growth-38.24%
EPS Growth9.35%
CountryUS
Employees156
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.85
Shares Outstanding155,447,430
10 Day Avg. Volume3,710,040
30 Day Avg. Volume4,082,116
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.52
Price to Sales (P/S)170.48
P/FCF Ratio-5.08
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue306.75
Enterprise Value/Gross Profit-23.31
Enterprise Value/Ebitda-7.60
Forecast
1Y Price Target
$7.64Price Target Upside113.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.79
Revenue Forecast (FY)$9.02M
AbSci Business Overview & Revenue Model
Company Description
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creati...
How the Company Makes Money
AbSci primarily makes money by providing drug discovery and development services to biopharmaceutical partners under collaboration agreements. Revenue is generally generated through (a) research and development service fees for conducting discover...
AbSci Earnings Call Summary
Earnings Call Date:Mar 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Positive
The call conveyed substantial progress and multiple near-term catalysts: first-in-human dosing for ABS-201 with favorable emerging safety/PK, an expanded indication into endometriosis with a planned Phase 2, published platform validation for de novo antibody design, strong survey-based commercial interest, and a stated cash runway into 2028. Counterbalancing these positives are modest current revenue, increased R&D spend (+37.5% YoY for the quarter), a sequential cash decline (-5.4%), early-stage clinical evidence with limited exposure, and competitive/regulatory uncertainties. On balance, the momentum on clinical advancement, platform differentiation, and market interest outweigh the present financial burn and early-stage risks.Positive Updates
Clinical Progress — ABS-201 Dosing and Early Safety/PK
Dosed first three SAD cohorts (roughly ~24 participants estimated) in ongoing Phase 1/2a headline trial; ABS-201 reported as well tolerated with favorable emerging safety data and emerging PK that supports the modeled dosing regimen. Planned milestones: preliminary safety/tolerability/PK data in H1 2026, interim 13-week proof-of-concept (POC) in H2 2026, and full 26-week POC in early 2027. Trial design enrolls up to 227 participants and includes SAD and MAD portions with MAD powered for AGA POC.
Negative Updates
Limited Near-Term Revenue
Q4 revenue was modest at $700,000, reflecting early-stage commercialization and reliance on partnered program revenue rather than product sales.
Read all updates
Q4-2025 Updates
Positive
Negative
Clinical Progress — ABS-201 Dosing and Early Safety/PK
Dosed first three SAD cohorts (roughly ~24 participants estimated) in ongoing Phase 1/2a headline trial; ABS-201 reported as well tolerated with favorable emerging safety data and emerging PK that supports the modeled dosing regimen. Planned milestones: preliminary safety/tolerability/PK data in H1 2026, interim 13-week proof-of-concept (POC) in H2 2026, and full 26-week POC in early 2027. Trial design enrolls up to 227 participants and includes SAD and MAD portions with MAD powered for AGA POC.
Read all positive updates
Company Guidance
Management provided specific clinical and commercial guidance for ABS‑201: the randomized, double‑blind Phase 1/2a (up to 227 healthy volunteers with/without AGA) has dosed the first three SAD cohorts (roughly ~24 participants), is evaluating four IV SAD dose groups followed by three SC MAD groups, and is on track to dose SAD cohort 4 and the first MAD cohort; preliminary safety/tolerability/PK data are expected in H1 2026, an interim 13‑week proof‑of‑concept readout in H2 2026, full 26‑week POC data in early 2027, and safety/PK from this study is planned to support initiation of a Phase 2 endometriosis trial in Q4 2026 (interim endo readout in 2027); key product metrics include a 3–4× longer preclinical half‑life vs a competitor, an anticipated dosing regimen of ~2–3 subcutaneous administrations over ~6 months with 2–3 year durability, a target efficacy comparable to high‑dose oral minoxidil (~35–40 hairs/cm²), and platform efficiencies of ~2 years and ~$15M to IND versus typical 4–6 years and ≥$50M; commercial and market figures cited include a U.S. AGA addressable population of ~15–18M (annual treatable volume 5–9M), consumer survey of 610 participants showing 87% of men/69% of women extremely/very likely to ask about ABS‑201 (rising to 92%/89% among oral minoxidil users), >30,000 potential U.S. retail locations, a U.S. TAM conceptually exceeding $25B, and endometriosis prevalence ~10% of women of reproductive age worldwide; financials: Q4 revenue $0.7M, R&D $25.3M (vs $18.4M prior year), SG&A $8.6M (vs $8.8M), $5.1M gain on contingent consideration (net $8.7M unrestricted), cash/cash equivalents/marketable securities $144.3M (Sept 30, 2025: $152.5M), and management believes runway into 2028.AbSci Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.80M | 4.53M | 5.72M | 5.75M | 4.78M |
| Gross Profit | -8.94M | -57.92M | -41.85M | -53.16M | -39.80M |
| EBITDA | -112.98M | -94.10M | -79.68M | -93.71M | -67.68M |
| Net Income | -115.18M | -103.11M | -110.57M | -104.90M | -100.96M |
Balance Sheet | |||||
| Total Assets | 216.30M | 213.61M | 217.30M | 321.01M | 426.19M |
| Cash, Cash Equivalents and Short-Term Investments | 144.29M | 112.42M | 97.66M | 164.43M | 252.57M |
| Total Debt | 5.30M | 10.11M | 15.88M | 22.98M | 20.01M |
| Total Liabilities | 26.85M | 34.48M | 41.12M | 46.59M | 60.09M |
| Stockholders Equity | 189.45M | 179.13M | 176.18M | 274.41M | 366.11M |
Cash Flow | |||||
| Free Cash Flow | -94.03M | -72.81M | -65.50M | -97.51M | -98.64M |
| Operating Cash Flow | -92.92M | -72.40M | -64.64M | -81.34M | -60.60M |
| Investing Cash Flow | -50.16M | -41.58M | 81.94M | -126.98M | -67.38M |
| Financing Cash Flow | 105.95M | 82.53M | -4.48M | 5.24M | 336.19M |
AbSci Technical Analysis
Positive
3.58
Price Trends
2.79
Positive
3.06
Positive
3.11
Positive
Market Momentum
0.13
Negative
70.70
Negative
78.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABSI, the sentiment is Positive. The current price of 3.58 is above the 20-day moving average (MA) of 3.02, above the 50-day MA of 2.79, and above the 200-day MA of 3.11, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 70.70 is Negative, neither overbought nor oversold. The STOCH value of 78.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABSI.
AbSci Risk Analysis
AbSci disclosed 83 risk factors in its most recent earnings report. AbSci reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AbSci Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $822.56M | -9.27 | -33.07% | ― | ― | -20.34% | |
54 Neutral | $873.61M | -4.45 | -59.68% | ― | -38.24% | 9.35% | |
52 Neutral | $493.47M | 5.60 | -31.75% | ― | 230194.59% | 20.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $417.84M | -1.47 | -99.00% | ― | 645.87% | -24.53% | |
47 Neutral | $468.06M | -4.38 | 66.23% | ― | 4.43% | 27.41% |
* Healthcare Sector Average
ABSI
AbSci
5.62
2.97
112.08%
AUTL
Autolus Therapeutics
1.57
0.39
33.05%
ADCT
ADC Therapeutics
3.68
2.39
185.27%
FDMT
4D Molecular Therapeutics
9.44
6.36
206.49%
DSGN
Design Therapeutics
13.17
9.54
262.81%
AbSci Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Absci Reports 2025 Results and Advances ABS-201 Program
Positive
Mar 24, 2026
On March 24, 2026, Absci reported fourth quarter and full-year 2025 results, highlighting clinical progress on ABS-201, its anti-PRLR antibody for androgenetic alopecia and endometriosis, including successful dosing of the first three cohorts in t...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Absci Updates Leadership Indemnification Agreements Amid Governance Focus
Positive
Mar 6, 2026
On March 6, 2026, Absci’s board approved amended and restated indemnification agreements for its directors and officers under Delaware law, refining change-of-control definitions, extending coverage for separate counsel in such events, and a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.